1. Nucleotide-Binding Oligomerization Domain 1 (NOD1) Agonists Prevent SARS-CoV-2 Infection in Human Lung Epithelial Cells through Harnessing the Innate Immune Response.
- Author
-
Garcia-Vidal E, Calba I, Riveira-Muñoz E, García E, Clotet B, Serra-Mitjà P, Cabrera C, Ballana E, and Badia R
- Subjects
- Humans, A549 Cells, Antiviral Agents pharmacology, COVID-19 Drug Treatment, Diaminopimelic Acid analogs & derivatives, Diaminopimelic Acid pharmacology, Immunity, Innate drug effects, Interleukin-8 metabolism, NF-kappa B metabolism, Nod2 Signaling Adaptor Protein agonists, Nod2 Signaling Adaptor Protein metabolism, Signal Transduction drug effects, COVID-19 immunology, COVID-19 virology, Epithelial Cells virology, Epithelial Cells metabolism, Epithelial Cells drug effects, Epithelial Cells immunology, Lung immunology, Lung virology, Lung metabolism, Nod1 Signaling Adaptor Protein metabolism, Nod1 Signaling Adaptor Protein agonists, SARS-CoV-2 physiology, SARS-CoV-2 immunology
- Abstract
The lung is prone to infections from respiratory viruses such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). A challenge in combating these infections is the difficulty in targeting antiviral activity directly at the lung mucosal tract. Boosting the capability of the respiratory mucosa to trigger a potent immune response at the onset of infection could serve as a potential strategy for managing respiratory infections. This study focused on screening immunomodulators to enhance innate immune response in lung epithelial and immune cell models. Through testing various subfamilies and pathways of pattern recognition receptors (PRRs), the nucleotide-binding and oligomerization domain (NOD)-like receptor (NLR) family was found to selectively activate innate immunity in lung epithelial cells. Activation of NOD1 and dual NOD1/2 by the agonists TriDAP and M-TriDAP, respectively, increased the number of IL-8+ cells by engaging the NF-κB and interferon response pathways. Lung epithelial cells showed a stronger response to NOD1 and dual NOD1/2 agonists compared to control. Interestingly, a less-pronounced response to NOD1 agonists was noted in PBMCs, indicating a tissue-specific effect of NOD1 in lung epithelial cells without inducing widespread systemic activation. The specificity of the NOD agonist pathway was confirmed through gene silencing of NOD1 (siRNA) and selective NOD1 and dual NOD1/2 inhibitors in lung epithelial cells. Ultimately, activation induced by NOD1 and dual NOD1/2 agonists created an antiviral environment that hindered SARS-CoV-2 replication in vitro in lung epithelial cells.
- Published
- 2024
- Full Text
- View/download PDF